TY - JOUR
T1 - Comparison between insulin-induced hypoglycemia and growth hormone (GH)- releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults
AU - Aimaretti, G.
AU - Corneli, G.
AU - Razzore, P.
AU - Bellone, S.
AU - Baffoni, C.
AU - Arvat, E.
AU - Camanni, F.
AU - Ghigo, E.
PY - 1998
Y1 - 1998
N2 - There is now wide consensus that, within an appropriate clinical context, GH deficiency (GHD) in adults must be shown biochemically by provocative testing of GH secretion and that appropriate cut-off limits have to be defined for each provocative test. Insulin-induced hypoglycemia (ITT) is indicated as the test of choice, and severe GHD, to be treated with recombinant human GH replacement, is defined by a GH peak response to ITT of less than 3 μg/L. GHRH + arginine (GHRH+ARG) is one of the most promising tests in alternative to ITT. In fact, it has been reported as a potent, reproducible, and age-independent test and that it is able to distinguish between GHD and normal adults. The aim of the present study was to compare the GH response to ITT and GHRH+ARG in a large group of hypopituitary adults (n = 40; 29 male and 11 female; age: 36.4 ± 2.1 yr). The third centile limit of the peak GH response to ITT has been reported as 5 μg/L, whereas in our lab, that to GHRH+ARG is 16.5 μg/L. In hypopituitary adults, the mean peak GH response to ITT (1.5 ± 0.2 μg/L, range: 0.1-8.5 μg/L) was lower (P < 0.001) than that to GHRH+ARG (3.0 ± 0.4 μg/L, range 0.1-12.0 μg/L), though there was positive correlation (r = 0.61, P < 0.001) between the GH responses to the 2 tests. The peak GH response to GHRH +ARG, but not that to ITT, was positively (though weakly) associated with insulin-like growth factor-I levels (r = 0.35, P < 0.03). Childhood and adult onset GHD patients, as well as patients with single and multiple pituitary insufficiencies, had similar peak GH responses to ITT or GHRH+ARG. Analyzing individual GH responses, 4/40 (10%) of the hypopituitary patients had GH peaks higher than 5 μg/L after ITT; moreover, 3 other patients (7%) had GH peaks, after ITT, higher than 3 μg/L. On the other hand, after GHRH+ARG, all patients had GH peaks lower than 16.5 μg/L, whereas 21/40 (52.5%) had GH peaks higher than 3 μg/L. Because 3 μg/L is the arbitrary cut-off for ITT, the third centile limit of which is 5 μg/L, we arbitrarily considered 9 μg/L as the cut-off point for GHRH+ARG. It is noteworthy that 37/40 (92.5%) patients had a GH peak,. after GHRH+ARG, below this limit. In conclusion, our present results confirm that the ITT test is a reliable provocative test for the diagnosis of adult GHD, whereas they show that the GHRH+ARG test is, at least, as sensitive as the ITT test (provided that appropriate cut-off limits are considered). Note that even the arbitrary cut-off point below which severe GHD is demonstrated has to be appropriate to the potency of the test.
AB - There is now wide consensus that, within an appropriate clinical context, GH deficiency (GHD) in adults must be shown biochemically by provocative testing of GH secretion and that appropriate cut-off limits have to be defined for each provocative test. Insulin-induced hypoglycemia (ITT) is indicated as the test of choice, and severe GHD, to be treated with recombinant human GH replacement, is defined by a GH peak response to ITT of less than 3 μg/L. GHRH + arginine (GHRH+ARG) is one of the most promising tests in alternative to ITT. In fact, it has been reported as a potent, reproducible, and age-independent test and that it is able to distinguish between GHD and normal adults. The aim of the present study was to compare the GH response to ITT and GHRH+ARG in a large group of hypopituitary adults (n = 40; 29 male and 11 female; age: 36.4 ± 2.1 yr). The third centile limit of the peak GH response to ITT has been reported as 5 μg/L, whereas in our lab, that to GHRH+ARG is 16.5 μg/L. In hypopituitary adults, the mean peak GH response to ITT (1.5 ± 0.2 μg/L, range: 0.1-8.5 μg/L) was lower (P < 0.001) than that to GHRH+ARG (3.0 ± 0.4 μg/L, range 0.1-12.0 μg/L), though there was positive correlation (r = 0.61, P < 0.001) between the GH responses to the 2 tests. The peak GH response to GHRH +ARG, but not that to ITT, was positively (though weakly) associated with insulin-like growth factor-I levels (r = 0.35, P < 0.03). Childhood and adult onset GHD patients, as well as patients with single and multiple pituitary insufficiencies, had similar peak GH responses to ITT or GHRH+ARG. Analyzing individual GH responses, 4/40 (10%) of the hypopituitary patients had GH peaks higher than 5 μg/L after ITT; moreover, 3 other patients (7%) had GH peaks, after ITT, higher than 3 μg/L. On the other hand, after GHRH+ARG, all patients had GH peaks lower than 16.5 μg/L, whereas 21/40 (52.5%) had GH peaks higher than 3 μg/L. Because 3 μg/L is the arbitrary cut-off for ITT, the third centile limit of which is 5 μg/L, we arbitrarily considered 9 μg/L as the cut-off point for GHRH+ARG. It is noteworthy that 37/40 (92.5%) patients had a GH peak,. after GHRH+ARG, below this limit. In conclusion, our present results confirm that the ITT test is a reliable provocative test for the diagnosis of adult GHD, whereas they show that the GHRH+ARG test is, at least, as sensitive as the ITT test (provided that appropriate cut-off limits are considered). Note that even the arbitrary cut-off point below which severe GHD is demonstrated has to be appropriate to the potency of the test.
UR - https://www.scopus.com/pages/publications/0031753015
U2 - 10.1210/jc.83.5.1615
DO - 10.1210/jc.83.5.1615
M3 - Article
SN - 0021-972X
VL - 83
SP - 1615
EP - 1618
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 5
ER -